29 related articles for article (PubMed ID: 36891979)
1. The association between jaundice and poorly differentiated pancreatic neuroendocrine neoplasms (Ki67 index > 55.0%).
Liu Y; Wang J; Zhou H; Wei Z; Wang J; Wang Z; Chen X
BMC Gastroenterol; 2023 Dec; 23(1):436. PubMed ID: 38087239
[TBL] [Abstract][Full Text] [Related]
2. The association between non-HDL cholesterol and high-grade pancreatic neuroendocrine neoplasms.
Zhou H; Zhu Y; Qin B; Liu Y; Wang Z; Guo C; Wang J; Chen X
Endocrine; 2024 Jun; ():. PubMed ID: 38844608
[TBL] [Abstract][Full Text] [Related]
3. [Prognostic value of carcinoembryonic antigen, alpha fetoprotein, carbohydrate antigen 125 and carbohydrate antigen 19-9 in gastroenteropancreatic neuroendocrine neoplasms].
Chen L; Zhang Y; Chen M; Chen J
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Sep; 20(9):1002-1008. PubMed ID: 28900990
[TBL] [Abstract][Full Text] [Related]
4. Applicative Value of Serum CA19-9, CEA, CA125 and CA242 in Diagnosis and Prognosis for Patients with Pancreatic Cancer Treated by Concurrent Chemoradiotherapy.
Gu YL; Lan C; Pei H; Yang SN; Liu YF; Xiao LL
Asian Pac J Cancer Prev; 2015; 16(15):6569-73. PubMed ID: 26434876
[TBL] [Abstract][Full Text] [Related]
5. The prognostic value of CEA, beta HCG, AFP, CA125, CA19-9 and C-erb B-2, beta HCG immunohistochemistry in advanced colorectal cancer.
Webb A; Scott-Mackie P; Cunningham D; Norman A; Andreyev J; O'Brien M; Bensted J
Ann Oncol; 1995 Jul; 6(6):581-7. PubMed ID: 8573538
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic role and prognostic value of tumor markers in high-grade gastro-enteropancreatic neuroendocrine neoplasms.
Gao C; Fan Z; Yang J; Shi M; Li Y; Zhan H
Pancreatology; 2023 Mar; 23(2):204-212. PubMed ID: 36710224
[TBL] [Abstract][Full Text] [Related]
7. Preoperative serum carbohydrate antigen 125 level is an independent negative prognostic marker for overall survival in colorectal cancer.
Yang XQ; Li Y; Chen C; Peng CW; Liu SP; Liu Y
Med Oncol; 2011 Sep; 28(3):789-95. PubMed ID: 20373053
[TBL] [Abstract][Full Text] [Related]
8. EGFR is a potential therapeutic target for highly glycosylated and aggressive pancreatic neuroendocrine neoplasms.
Xiao Z; Xu H; Strosberg JR; Lu R; Zhu X; Deng S; Ding L; Ni Q; Warshaw AL; Yu X; Luo G
Int J Cancer; 2023 Jul; 153(1):164-172. PubMed ID: 36891979
[TBL] [Abstract][Full Text] [Related]
9. A systematic review and meta-analysis of the clinicopathologic characteristics of cystic versus solid pancreatic neuroendocrine neoplasms.
Koh YX; Chok AY; Zheng HL; Tan CS; Goh BK
Surgery; 2014 Jul; 156(1):83-96.e2. PubMed ID: 24878455
[TBL] [Abstract][Full Text] [Related]
10. Pathology and Surgical Treatment of High-Grade Pancreatic Neuroendocrine Carcinoma: an Evolving Landscape.
Haugvik SP; Kaemmerer D; Gaujoux S; Labori KJ; Verbeke CS; Gladhaug IP
Curr Oncol Rep; 2016 May; 18(5):28. PubMed ID: 26984415
[TBL] [Abstract][Full Text] [Related]
11. Pancreatic Neuroendocrine Neoplasms and Gastrointestinal Stromal Tumors: A Single-Institution Experience of a Rare Association and Review of the Literature.
Milanetto AC; Pacciani S; Fassan M; Pasquali C
Pancreas; 2020 Aug; 49(7):918-923. PubMed ID: 32658075
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
